Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More Sep 1 2022 | Heart Failure Awareness 365: Types of Heart Failure and Related Conditions/Diseases Patient News Heart Failure Awareness 365 Patient Resource Read More Aug 11 2022 | University of Maryland Surgical Team Who Conducted Historic Xenotransplantation to Speak in Plenary Session at HFSA Annual Scientific Meeting 2022 HFSA News Annual Scientific Meeting Press Release Provider Education Research Read More Aug 4 2022 | Seeking Hosts for Heart Failure Beat Podcast Read More Pagination First page « First Previous page ‹ Previous … Page 57 Page 58 Page 59 Page 60 Current page 61 Page 62 Page 63 Page 64 Page 65 … Next page Next › Last page Last »
Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More
Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More
Sep 1 2022 | Heart Failure Awareness 365: Types of Heart Failure and Related Conditions/Diseases Patient News Heart Failure Awareness 365 Patient Resource Read More
Aug 11 2022 | University of Maryland Surgical Team Who Conducted Historic Xenotransplantation to Speak in Plenary Session at HFSA Annual Scientific Meeting 2022 HFSA News Annual Scientific Meeting Press Release Provider Education Research Read More
